These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 6161964

  • 1. The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein Barr infection is mediated by interferon.
    Thorley-Lawson DA.
    J Immunol; 1981 Mar; 126(3):829-33. PubMed ID: 6161964
    [Abstract] [Full Text] [Related]

  • 2. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.
    Thorley-Lawson DA.
    J Immunol; 1980 Feb; 124(2):745-51. PubMed ID: 6243331
    [Abstract] [Full Text] [Related]

  • 3. T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals.
    Tosato G, Magrath IT, Blaese RM.
    J Immunol; 1982 Feb; 128(2):575-9. PubMed ID: 6274959
    [Abstract] [Full Text] [Related]

  • 4. Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis).
    Tosato G, Straus S, Henle W, Pike SE, Blaese RM.
    J Immunol; 1985 May; 134(5):3082-8. PubMed ID: 2984282
    [Abstract] [Full Text] [Related]

  • 5. Suppressor T cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis.
    Wang F, Blaese RM, Zoon KC, Tosato G.
    J Clin Invest; 1987 Jan; 79(1):7-14. PubMed ID: 3025263
    [Abstract] [Full Text] [Related]

  • 6. [IFN production by Epstein-Barr virus in human mononuclear leukocytes and suppression of the virus-induced transformation by the endogenous interferon].
    Kikuta H.
    Hokkaido Igaku Zasshi; 1986 Jan; 61(1):46-57. PubMed ID: 3009290
    [Abstract] [Full Text] [Related]

  • 7. B cells under influence: transformation of B cells by Epstein-Barr virus.
    Küppers R.
    Nat Rev Immunol; 2003 Oct; 3(10):801-12. PubMed ID: 14523386
    [Abstract] [Full Text] [Related]

  • 8. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis.
    Klein E, Ernberg I, Masucci MG, Szigeti R, Wu YT, Masucci G, Svedmyr E.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4210-5. PubMed ID: 6272964
    [Abstract] [Full Text] [Related]

  • 9. A study of the functional capabilities of human neonatal lymphocytes for in vitro specific antibody production.
    Yarchoan R, Nelson DL.
    J Immunol; 1983 Sep; 131(3):1222-8. PubMed ID: 6309961
    [Abstract] [Full Text] [Related]

  • 10. [Immunologic protection against Epstein-Barr virus induced oncogenesis: cooperative effect of lymphocytes, antibodies and interferon in healthy individuals (author's transl)].
    Aya T.
    Hokkaido Igaku Zasshi; 1981 Nov; 56(6):587-96. PubMed ID: 6175556
    [Abstract] [Full Text] [Related]

  • 11. The MLC response of patients with infectious mononucleosis to Epstein-Barr virus-transformed cells.
    Wasik M, Myc A, Matej H, Rudzka L.
    Arch Immunol Ther Exp (Warsz); 1983 Nov; 31(6):871-8. PubMed ID: 6331340
    [Abstract] [Full Text] [Related]

  • 12. The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes.
    Stuart AD, Stewart JP, Arrand JR, Mackett M.
    Oncogene; 1995 Nov 02; 11(9):1711-9. PubMed ID: 7478598
    [Abstract] [Full Text] [Related]

  • 13. Human B lymphocytes activated by Epstein-Barr virus (EBV) or by mitogens suppress mitogen-induced immunoglobulin production.
    Tsukuda K, Berczi I, Klein G.
    J Immunol; 1981 May 02; 126(5):1810-3. PubMed ID: 6260858
    [Abstract] [Full Text] [Related]

  • 14. Human T cell hybridomas specific for Epstein Barr virus-infected B lymphocytes.
    Lakow E, Tsoukas CD, Vaughan JH, Altman A, Carson DA.
    J Immunol; 1983 Jan 02; 130(1):169-72. PubMed ID: 6292301
    [Abstract] [Full Text] [Related]

  • 15. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.
    Wingate PJ, McAulay KA, Anthony IC, Crawford DH.
    J Med Virol; 2009 May 02; 81(5):870-7. PubMed ID: 19319950
    [Abstract] [Full Text] [Related]

  • 16. Cellular immune defects to Epstein-Barr virus-determined antigens in young males.
    Masucci MG, Szigeti R, Ernberg I, Masucci G, Klein G, Chessels J, Sieff C, Lie S, Glomstein A, Businco L, Henle W, Henle G, Pearson G, Sakamoto K, Purtilo DT.
    Cancer Res; 1981 Nov 02; 41(11 Pt 1):4284-91. PubMed ID: 6171337
    [Abstract] [Full Text] [Related]

  • 17. Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.
    Suzuki T, Piche A, Kasono K, Xiang J, Gomez-Navarro J, Moriuchi S, Krisky DM, Oligino T, Glorioso JC, Curiel TJ, Curiel DT.
    Biochem Biophys Res Commun; 1998 Nov 27; 252(3):686-90. PubMed ID: 9837767
    [Abstract] [Full Text] [Related]

  • 18. Clinical and immunological considerations in Epstein-Barr virus-associated diseases.
    Andersson J.
    Scand J Infect Dis Suppl; 1996 Nov 27; 100():72-82. PubMed ID: 8860357
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus-specific serology in immunologically compromised individuals.
    Henle W, Henle G.
    Cancer Res; 1981 Nov 27; 41(11 Pt 1):4222-5. PubMed ID: 6272966
    [Abstract] [Full Text] [Related]

  • 20. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH, Wolf H, Minarovits J.
    Autoimmunity; 2008 May 27; 41(4):298-328. PubMed ID: 18432410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.